Preclinical News and Research

RSS

Morphotek acquires tumor targeting assets from TMI

Morphotek, Inc., a subsidiary of Eisai Inc., announced today that it has acquired certain assets relating to a proprietary tumor targeting platform from TransMolecular, Inc. for an undisclosed upfront payment and future development milestones.

4 Apr 2011

Sofie Biosciences launches GENISYS4 benchtop small animal PET system

Sofie Biosciences, a developer of molecular imaging systems and agents, announced the launch of GENISYS4, their new benchtop small animal PET system. Introduced today at the 2011 American Association for Cancer Research Annual Meeting, this compact, preclinical multimodality PET system provides researchers with the ability to non-invasively visualize and measure the biology of disease and therapeutic response over the course of a study.

4 Apr 2011

ImmunoGen presents IMGN529 data against NHL, CLL at AACR meeting

ImmunoGen, Inc., a biotechnology company that develops targeted antibody-based anticancer products using its antibody expertise and Targeted Antibody Payload technology, today disclosed the profile and first preclinical data for the Company's novel IMGN529 product candidate for the treatment of B-cell malignancies including non-Hodgkin's lymphoma and chronic lymphocytic leukemia.

4 Apr 2011

Oncothyreon's ONT-10, PX-866 preclinical data presented at AACR meeting

Oncothyreon Inc. today announced the presentation of preclinical data for ONT-10, a therapeutic vaccine directed at cancers expressing MUC1, and PX-866, its irreversible inhibitor of phosphatidylinositol 3-kinase, at the American Association of Cancer Research meeting in Orlando, Florida.

4 Apr 2011

ImmunoGen presents IMGN853 data against ovarian cancer, carcinomas at AACR meeting

ImmunoGen, Inc., a biotechnology company that develops targeted anticancer products using its antibody expertise and Targeted Antibody Payload technology, today announced the reporting of the first data on the Company's IMGN853 product candidate for the treatment of ovarian cancer and other types of solid tumors.

4 Apr 2011

Stealth announces Bendavia Phase I clinical study results against ischemia reperfusion injury

Stealth Peptides Inc., a privately held biopharmaceutical company developing innovative therapies, announced today the results of a healthy volunteers Phase I clinical study of Bendavia™, a novel compound that targets the mitochondrion to treat ischemia reperfusion injury.

4 Apr 2011

Human immune system can help predict recurrence, overall breast cancer survival

A study published in Cancer Discovery, the newest journal of the American Association for Cancer Research, debuting here at the AACR 102nd Annual Meeting 2011, held April 2-6, showed how evaluating the immune response in the tumor microenvironment may help researchers better target therapy in breast cancer.

4 Apr 2011

New research reveals potential treatment for HO in children, soldiers

Promising new research reveals a potentially highly effective treatment for heterotopic ossification, a painful and often debilitating abnormal buildup of bone tissue. HO comes in two main forms—one that appears in children and is congenital, another that strikes wounded military personnel and surgery patients and is triggered by severe injuries and wounds.

4 Apr 2011

Entry inhibitors can provide first new hepatitis B & D treatments for many years

Promising new viral hepatitis data presented today at the International Liver CongressTM show that entry inhibitors --a new mechanism of action for drugs to treat viral hepatitis -- could provide the first new hepatitis B and hepatitis D treatments for many years.

2 Apr 2011

Experts must monitor new antiviral compounds for HCV treatment

Data presented at the International Liver CongressTM highlight the fact that new novel antiviral compounds for the treatment of hepatitis C virus must be prescribed and monitored by experts and specialists to ensure resistance is minimised.

2 Apr 2011

Pfizer to present new investigational compounds data against cancer at AACR meeting

Pfizer Oncology will present nearly 30 abstracts highlighting research in new and established pathways, including inhibition of Hedgehog signaling; dual inhibition of PI3K/mTOR; and cancer stem cell-based targets.

2 Apr 2011

Three abstracts from SuperGen PIM kinase inhibitor program to be presented at AACR

SuperGen, Inc., a pharmaceutical company dedicated to the discovery and development of novel cancer therapies, today announced the acceptance of three abstracts from the SuperGen PIM kinase inhibitor program. Poster presentations by SuperGen and collaborators will occur on April 3 and 5, 2011 at the American Association for Cancer Research 102nd Annual Meeting in Orlando, Florida.

2 Apr 2011

PBI commits to sponsor APS Novel Disease Model Awards for 2011 through 2013

Plato BioPharma, Inc. announced today that the company has committed to sponsor The American Physiological Society's Novel Disease Model Awards for 2011 through 2013.

2 Apr 2011

Champions enters exclusive license agreement with BCCA for Irinophore C

Champions Biotechnology, Inc. announced today that it has exercised an option to license Irinophore C, a liposomal formulation of Irinotecan, from the BC Cancer Agency in British Columbia, Canada.

2 Apr 2011

Results of Boehringer Ingelheim's BI 201335 study presented at Annual Meeting of EASL

New data presented today at the 46th Annual Meeting of the European Association for the Study of the Liver demonstrate the antiviral activity of Boehringer Ingelheim's once-daily oral protease inhibitor, BI 201335, in both treatment-naive and -experienced patients with chronic genotype-1 hepatitis C virus, the most challenging genotype of HCV to treat.

1 Apr 2011

Neogenix Oncology to present laboratory studies of NEO-101 at AACR Annual Meeting

Neogenix Oncology, Inc. announced today that members of its scientific staff will present laboratory studies of NEO-101, a novel monoclonal antibody in development to diagnose and treat pancreatic and colorectal cancers.

1 Apr 2011

Study shows immune therapy can prevent pregnancy in mammals including humans

Researchers at Weill Cornell Medical College have shown that it is possible to immunize mammals to control fertility. They say their technique could possibly be used on other mammals -- including humans -- because fertility hormones and their receptors are species-non-specific and are similar in both females and males.

1 Apr 2011

VBL's VB-111 preclinical data against metastatic cancer to be presented at AACR meeting

VBL Therapeutics, a clinical-stage biotechnology company committed to the development of novel treatments for immune-inflammatory diseases and cancer, today announced two upcoming presentations of preclinical data from the company's VB-111 program at the American Association for Cancer Research 102nd Annual Meeting.

1 Apr 2011

Anavex screening volunteers for phase I, first-in-human clinical study in Alzheimer’s

Anavex Life Sciences Corp. today announced screening of the first healthy volunteers for the Phase I clinical study of ANAVEX 2-73, its lead compound for the treatment of Alzheimer’s disease. ANAVEX 2-73 is the first of a new class of wholly-owned, oral, disease-modifying compounds, which act through sigma-1 receptor agonist as well as muscarinic cholinergic effects and up-regulation of Bcl-2.

31 Mar 2011

Immune therapy can control fertility in mammals

31 Mar 2011

Preclinical News and Research

Morphotek acquires tumor targeting assets from TMI

Sofie Biosciences launches GENISYS4 benchtop small animal PET system

ImmunoGen presents IMGN529 data against NHL, CLL at AACR meeting

Oncothyreon's ONT-10, PX-866 preclinical data presented at AACR meeting

ImmunoGen presents IMGN853 data against ovarian cancer, carcinomas at AACR meeting

Stealth announces Bendavia Phase I clinical study results against ischemia reperfusion injury

Human immune system can help predict recurrence, overall breast cancer survival

New research reveals potential treatment for HO in children, soldiers

Entry inhibitors can provide first new hepatitis B & D treatments for many years

Experts must monitor new antiviral compounds for HCV treatment

Pfizer to present new investigational compounds data against cancer at AACR meeting

Three abstracts from SuperGen PIM kinase inhibitor program to be presented at AACR

PBI commits to sponsor APS Novel Disease Model Awards for 2011 through 2013

Champions enters exclusive license agreement with BCCA for Irinophore C

Results of Boehringer Ingelheim's BI 201335 study presented at Annual Meeting of EASL

Neogenix Oncology to present laboratory studies of NEO-101 at AACR Annual Meeting

Study shows immune therapy can prevent pregnancy in mammals including humans

VBL's VB-111 preclinical data against metastatic cancer to be presented at AACR meeting

Anavex screening volunteers for phase I, first-in-human clinical study in Alzheimer’s

Immune therapy can control fertility in mammals

Sensing a Healthier Future

Achieving and maintaining ISO/IEC 27001 and BS 10012 certifications

Expanding research and clinical options for children with cancer

Latest Life Science News